Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Treatment Collaborates with University of Minnesota Medical School to test AI


VANCOUVER, British Columbia, Oct. 12, 2021 (GLOBE NEWSWIRE) -- International Inc. (“Treatment” or “The Company”) (CSE: TRUE), (OTC: TREIF), a healthcare AI technology company, has collaborated with the University of Minnesota Medical School (U of M Medical School) to test its innovative and proprietary healthcare AI.

Dr. Kevin A. Peterson, MD, MPH, FRCS(Ed), FAAFP and Chief Medical Officer of Treatment, says, “By working with the U of M medical students, we have the opportunity to test our AI approach against textbook medical school cases. The students also have the opportunity to challenge their knowledge against the AI engine, furthering their understanding of primary care diagnostic assessments and providing an opportunity to support doctors in making better clinical evaluations in the future.”

The U of M Medical School’s faculty will be rigorously testing Treatment’s AI engine, named MERLIN, and evaluating its ability to improve and assist the healthcare assessments of third-and fourth-year medical students. The testing will assess the MERLIN’s ability to successfully identify the most common diseases based on a patient’s presentation of symptoms.

“So much of primary care can be captured in the top 500 diseases. When we can confidently assess and treat those conditions, the health of the entire population stands to improve. With more rigorous testing, our AI platform improves even more and offers us additional opportunities to use our technology with doctors in real medical clinics and environments,” says Dr. Peterson.

In addition to MERLIN, Cara, Treatment’s much anticipated first product, is a mobile application for health assessment that will leverage the same AI engine tested by the U of M Medical School. Cara is set to launch this year.

About is a disruptive healthcare technology company that is harnessing the power of AI to help consumers improve their health through personalized recommendations and insights. Based in Vancouver and Minneapolis, the company spent the last five years working with a team of world-class doctors, engineers, mathematicians, and AI specialists to develop a complex AI engine that leverages the most robust, personalized data to generate highly predictive and accurate insights. is the parent company of Cara. Cara empowers consumers to take control of their health with the launch of an innovative mobile app powered by this exclusive AI engine.

For more investor information on please visit

Forward Looking Statement

This news release contains forward-looking statements relating to the future operations of, International, Inc. (Treatment) and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

For more information:

Investor Contact:

Primary Logo